ArticleNature protocols2014
A nanoparticle formula for delivering siRNA or miRNAs to tumor cells in cell culture and in vivo.
Article in Nature protocols, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Novel ruthenium(II) polypyridyl complexes conjugated with bis-dipicolylamine as antibacterial photosensitisers.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2025Article
- Dual-targeted siRubicon delivery strategy triggers hepatocellular lipophagy for mitigating liver steatosis.Nature communications · 2025Article
- Nanoparticles-Delivered Circular RNA Strategy as a Novel Antitumor Approach.International journal of molecular sciences · 2024Review
- Reprogramming of T cell-derived small extracellular vesicles using IL2 surface engineering induces potent anti-cancer effects through miRNA delivery.Journal of extracellular vesicles · 2022Article
- miRNAs in Cancer (Review of Literature).International journal of molecular sciences · 2022Review
- Current Limitations and Recent Progress in Nanomedicine for Clinically Available Photodynamic Therapy.Biomedicines · 2021Review
- Advances in Multiple Stimuli-Responsive Drug-Delivery Systems for Cancer Therapy.International journal of nanomedicine · 2021Review
- Binary Targeting of siRNA to Hematologic Cancer CellsAdvanced functional materials · 2019Article
- Cholangiocarcinoma therapy with nanoparticles that combine downregulation of MicroRNA-210 with inhibition of cancer cell invasiveness.Theranostics · 2018Article
- A bone-resorption surface-targeting nanoparticle to deliver anti-miR214 for osteoporosis therapy.International journal of nanomedicine · 2017Article
- Preparation and Characterization of Hyaluronic Acid-Polycaprolactone Copolymer Micelles for the Drug Delivery of Radioactive Iodine-131 Labeled Lipiodol.BioMed research international · 2017Article
- Imaging-guided delivery of RNAi for anticancer treatment.Advanced drug delivery reviews · 2016Review
- Imaging and therapeutic applications of zinc(ii)-dipicolylamine molecular probes for anionic biomembranes.Chemical communications (Cambridge, England) · 2016Review
- A novel paclitaxel-loaded poly(d,l-lactide-co-glycolide)-Tween 80 copolymer nanoparticle overcoming multidrug resistance for lung cancer treatment.International journal of nanomedicine · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
To improve RNA delivery, we present a protocol to produce an RNA carrier based on a Zn(II)-dipicolylamine (Zn-DPA) analog, which is an artificial receptor for phosphate anion derivatives. We further functionalized this Zn-DPA analog to hyaluronic acid (HA)-based self-assembled nanoparticles (HA-NPs) with a hydrodynamic diameter of 100 nm by conjugating amine-functionalized Zn-DPA molecules onto the HA-NPs through amide formation, resulting in efficient tumor-targeted delivery of RNAs (siRNAs, miRNA or other short oligoribonucleotides) and small-molecule drugs. The functional group of Zn-DPA can be converted into other groups such as a carboxylic or thiol group, and the DPA analog can be covalently attached to a variety of existing and novel platforms or formulations for the development of multifunctional materials via standard bioconjugation techniques. Protocols for RNA formulation and delivery into tumor tissues and tumor cells are also described. Our design strategy offers a versatile and practical method for delivering both RNA and chemotherapeutics to tumor cells and expands existing nanomaterial capabilities to further the field of drug and gene delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.